Melanoma brain metastasis pseudoprogression after pembrolizumab treatment

Justine V. Cohen, Ahmed K. Alomari, Alexander Vortmeyer, Lucia B. Jilaveanu, Sarah B. Goldberg, Amit Mahajan, Veronica L. Chiang, Harriet M. Kluger

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

The role of immunotherapy in treatment of brain metastases is unknown because most trials exclude patients with active brain lesions. As new immunomodulating agents gain approval for many malignancies, it is important to know if they have unique effects in the central nervous system (CNS). Here, we present a case of a patient with progressing brain metastases treated with a single cycle of pembrolizumab, who presented with mental status changes 11 days thereafter. MRI of the brain showed enlargement of CNS lesions with intense central enhancement and diffuse perilesional edema. Histologic evaluation of a resected lesion revealed isolated clusters of tumor cells surrounded by reactive astrocytosis, scattered inflammatory cells, and an abundance of microglial cells. Given the increasing use of immune checkpoint inhibitors in patients with brain metastases from melanoma and other diseases, recognition of pseudoprogression and management with immune suppression are essential.

Original languageEnglish (US)
Pages (from-to)179-182
Number of pages4
JournalCancer Immunology Research
Volume4
Issue number3
DOIs
StatePublished - Mar 1 2016
Externally publishedYes

Fingerprint

Melanoma
Neoplasm Metastasis
Brain
Central Nervous System
Therapeutics
Gliosis
Immunotherapy
Edema
Neoplasms
pembrolizumab

ASJC Scopus subject areas

  • Immunology
  • Cancer Research

Cite this

Cohen, J. V., Alomari, A. K., Vortmeyer, A., Jilaveanu, L. B., Goldberg, S. B., Mahajan, A., ... Kluger, H. M. (2016). Melanoma brain metastasis pseudoprogression after pembrolizumab treatment. Cancer Immunology Research, 4(3), 179-182. https://doi.org/10.1158/2326-6066.CIR-15-0160

Melanoma brain metastasis pseudoprogression after pembrolizumab treatment. / Cohen, Justine V.; Alomari, Ahmed K.; Vortmeyer, Alexander; Jilaveanu, Lucia B.; Goldberg, Sarah B.; Mahajan, Amit; Chiang, Veronica L.; Kluger, Harriet M.

In: Cancer Immunology Research, Vol. 4, No. 3, 01.03.2016, p. 179-182.

Research output: Contribution to journalArticle

Cohen, JV, Alomari, AK, Vortmeyer, A, Jilaveanu, LB, Goldberg, SB, Mahajan, A, Chiang, VL & Kluger, HM 2016, 'Melanoma brain metastasis pseudoprogression after pembrolizumab treatment', Cancer Immunology Research, vol. 4, no. 3, pp. 179-182. https://doi.org/10.1158/2326-6066.CIR-15-0160
Cohen, Justine V. ; Alomari, Ahmed K. ; Vortmeyer, Alexander ; Jilaveanu, Lucia B. ; Goldberg, Sarah B. ; Mahajan, Amit ; Chiang, Veronica L. ; Kluger, Harriet M. / Melanoma brain metastasis pseudoprogression after pembrolizumab treatment. In: Cancer Immunology Research. 2016 ; Vol. 4, No. 3. pp. 179-182.
@article{3d4d5e8a372840af9dee07efa5489e95,
title = "Melanoma brain metastasis pseudoprogression after pembrolizumab treatment",
abstract = "The role of immunotherapy in treatment of brain metastases is unknown because most trials exclude patients with active brain lesions. As new immunomodulating agents gain approval for many malignancies, it is important to know if they have unique effects in the central nervous system (CNS). Here, we present a case of a patient with progressing brain metastases treated with a single cycle of pembrolizumab, who presented with mental status changes 11 days thereafter. MRI of the brain showed enlargement of CNS lesions with intense central enhancement and diffuse perilesional edema. Histologic evaluation of a resected lesion revealed isolated clusters of tumor cells surrounded by reactive astrocytosis, scattered inflammatory cells, and an abundance of microglial cells. Given the increasing use of immune checkpoint inhibitors in patients with brain metastases from melanoma and other diseases, recognition of pseudoprogression and management with immune suppression are essential.",
author = "Cohen, {Justine V.} and Alomari, {Ahmed K.} and Alexander Vortmeyer and Jilaveanu, {Lucia B.} and Goldberg, {Sarah B.} and Amit Mahajan and Chiang, {Veronica L.} and Kluger, {Harriet M.}",
year = "2016",
month = "3",
day = "1",
doi = "10.1158/2326-6066.CIR-15-0160",
language = "English (US)",
volume = "4",
pages = "179--182",
journal = "Cancer immunology research",
issn = "2326-6066",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Melanoma brain metastasis pseudoprogression after pembrolizumab treatment

AU - Cohen, Justine V.

AU - Alomari, Ahmed K.

AU - Vortmeyer, Alexander

AU - Jilaveanu, Lucia B.

AU - Goldberg, Sarah B.

AU - Mahajan, Amit

AU - Chiang, Veronica L.

AU - Kluger, Harriet M.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - The role of immunotherapy in treatment of brain metastases is unknown because most trials exclude patients with active brain lesions. As new immunomodulating agents gain approval for many malignancies, it is important to know if they have unique effects in the central nervous system (CNS). Here, we present a case of a patient with progressing brain metastases treated with a single cycle of pembrolizumab, who presented with mental status changes 11 days thereafter. MRI of the brain showed enlargement of CNS lesions with intense central enhancement and diffuse perilesional edema. Histologic evaluation of a resected lesion revealed isolated clusters of tumor cells surrounded by reactive astrocytosis, scattered inflammatory cells, and an abundance of microglial cells. Given the increasing use of immune checkpoint inhibitors in patients with brain metastases from melanoma and other diseases, recognition of pseudoprogression and management with immune suppression are essential.

AB - The role of immunotherapy in treatment of brain metastases is unknown because most trials exclude patients with active brain lesions. As new immunomodulating agents gain approval for many malignancies, it is important to know if they have unique effects in the central nervous system (CNS). Here, we present a case of a patient with progressing brain metastases treated with a single cycle of pembrolizumab, who presented with mental status changes 11 days thereafter. MRI of the brain showed enlargement of CNS lesions with intense central enhancement and diffuse perilesional edema. Histologic evaluation of a resected lesion revealed isolated clusters of tumor cells surrounded by reactive astrocytosis, scattered inflammatory cells, and an abundance of microglial cells. Given the increasing use of immune checkpoint inhibitors in patients with brain metastases from melanoma and other diseases, recognition of pseudoprogression and management with immune suppression are essential.

UR - http://www.scopus.com/inward/record.url?scp=84962016032&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962016032&partnerID=8YFLogxK

U2 - 10.1158/2326-6066.CIR-15-0160

DO - 10.1158/2326-6066.CIR-15-0160

M3 - Article

VL - 4

SP - 179

EP - 182

JO - Cancer immunology research

JF - Cancer immunology research

SN - 2326-6066

IS - 3

ER -